Cell Biotech Co. Ltd (049960) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Cell Biotech Co. Ltd KRW 15,078, price KRW 14,920, upside +1.1%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cell Biotech Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 9,031 KRW – 18,110 KRW · fair‑value band 11,247 KRW – 19,679 KRW · the 14,920 KRW price screens below the 15,078 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Cell Biotech Co. in your weekly email
Every Wednesday you see whether Cell Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd.
Show more
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.
Stock analysis
Cell Biotech Co. Ltd (049960) currently trades at 14,920 KRW, while our model-based Fair Value estimate is 15,078 KRW, implying the stock looks roughly 1.0% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 22,949 KRW per share, and 13 of the 23 models we run sit above the 14,920 KRW price.
Bear case: the Earnings-Based group reads lowest at 8,652 KRW, and 10 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: 11,247 KRW (bear) to 19,679 KRW (bull), the price of 14,920 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Cell Biotech Co. Ltd reported revenue of 53.1B KRW in FY2025 versus 46.9B KRW in FY2021, a compound +3.2%/yr. Reported net income was 10.1B KRW in FY2025, compounding −0.6%/yr from FY2021.
Key figures
Market cap 102B KRW (≈ $71.5M) · P/S ratio 2.16 · Dividend yield 3.4% · Net margin 19.1% · Return on equity 1,185% · Return on assets (EBIT) 4.9% · Operating margin 14.1% · Revenue (TTM) 48.8B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 1%, 049960 screens cheaper than that median.
Fair Value models
Bear 11,247 KRWFair Value 15,078 KRWBull 19,679 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Start year 2020 (pandemic). Over 10 years: +0.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.2%
Dividend (yield on the price)3.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8% vs −5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 15%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−29.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −30.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2614 stocks
Beats the sector median on 7/8 measures
Overall it ranks above its sector peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+1% · Above median
Profitability
Return on assets4% · Above median
Net margin (TTM)30% · Top 25%
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth−3% · Below median
Dividend yield (TTM)3.4% · Top 25%
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cell Biotech Co. Ltd (049960) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 15,078 KRW versus a price of 14,920 KRW, about +1% upside (fairly valued).
What is the fair value of 049960?
Our model-based fair value for Cell Biotech Co. Ltd is 15,078 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 14,920 KRW.
What is the quality score of 049960?
Cell Biotech Co. Ltd has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cell Biotech Co. Ltd (049960)?
Our model-based price target is the fair value of 15,078 KRW (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 11,247 KRW, optimistic scenario 19,679 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Cell Biotech Co. Ltd stock forecast for 2026?
Our models put fair value at 15,078 KRW, about +1% upside versus a price of 14,920 KRW (fairly valued). Cautious scenario 11,247 KRW, optimistic scenario 19,679 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cell Biotech Co. Ltd (049960)?
Cell Biotech Co. Ltd reported trailing-twelve-month revenue of about 48.8B KRW (latest available figure, as of Sep 24, 2026).
Does Cell Biotech Co. Ltd pay a dividend?
Cell Biotech Co. Ltd currently shows a dividend yield of about 3.41% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Cell Biotech Co. Ltd (049960)?
For today's price to be fair in a discounted-cash-flow model, Cell Biotech Co. Ltd would have to grow free cash flow by -29.3 % per year for five years (discount rate 13.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 049960 use?
Our models discount Cell Biotech Co. Ltd at 13.4 %: a base by market capitalisation (micro), damped by beta 1.09, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cell Biotech Co. Ltd that is -29.3 % per year a year over ten years, using the same discount rate (13.4 %) and the same formula as our fair value.
How much growth has Cell Biotech Co. Ltd (049960) delivered so far?
Over the past 5 years revenue at Cell Biotech Co. Ltd grew +3.1 % a year. The price currently implies -29.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cell Biotech Co. Ltd (049960) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Cell Biotech Co. Ltd (-29.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cell Biotech Co. Ltd (049960)?
The free-cash-flow yield on the price is 7.74 %: that much free cash flow Cell Biotech Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cell Biotech Co. Ltd (049960)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cell Biotech Co. Ltd it is 15,078 KRW per share (as of Sep 24, 2026), against a price of 14,920 KRW. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Cell Biotech Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 049960 trades below its calculated fair value: price 14,920 KRW, fair value 15,078 KRW, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 049960?
No. The price is what the market pays today (14,920 KRW); the fair value is what the company's own numbers justify (15,078 KRW). For Cell Biotech Co. Ltd the two are 157.55 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cell Biotech Co. Ltd worth?
The market values Cell Biotech Co. Ltd at about 102B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 14,920 KRW; our models calculate a fair value of 15,078 KRW per share.
What do the bullish and bearish scenarios say about 049960?
Our models span a range for Cell Biotech Co. Ltd: cautious scenario 11,247 KRW, base 15,078 KRW, optimistic 19,679 KRW per share (as of Sep 24, 2026, price 14,920 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 049960 from its 52-week high?
Cell Biotech Co. Ltd trades at 14,920 KRW, about 18% below its 52-week high of 18,110 KRW and 34% above the low of 11,121 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 15,078 KRW is for.
Which stocks are comparable to Cell Biotech Co. Ltd?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Macrogen, Inc, Panagene Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cell Biotech Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 14,920 KRW, calculated fair value 15,078 KRW (+1%), Quality Score 67/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 049960 calculated?
We run Cell Biotech Co. Ltd through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 15,078 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Cell Biotech Co. Ltd currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cell Biotech Co. Ltd (049960)?
The closing price on Sep 23, 2026 was 14,920 KRW. Our model-based fair value is 15,078 KRW, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cell Biotech Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Cell Biotech Co. Ltd
How large is the market capitalisation of Cell Biotech Co. Ltd (049960)?
The market capitalisation of Cell Biotech Co. Ltd is 102B KRW (≈ $71.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cell Biotech Co. Ltd (049960)?
The price-to-sales ratio of Cell Biotech Co. Ltd is 2.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Cell Biotech Co. Ltd (049960)?
The dividend yield of Cell Biotech Co. Ltd is 3.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cell Biotech Co. Ltd (049960)?
The net margin of Cell Biotech Co. Ltd is 19.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cell Biotech Co. Ltd (049960)?
The return on equity (ROE) of Cell Biotech Co. Ltd is 1,185% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cell Biotech Co. Ltd (049960)?
On an EBIT basis the return on assets of Cell Biotech Co. Ltd is 4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cell Biotech Co. Ltd (049960)?
The operating margin of Cell Biotech Co. Ltd is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cell Biotech Co. Ltd (049960)?
Revenue at Cell Biotech Co. Ltd is growing −2.6% versus a year earlier (3y avg +1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cell Biotech Co. Ltd (049960)?
Earnings per share at Cell Biotech Co. Ltd are growing +46.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Cell Biotech Co. Ltd in the live analysis
One click puts Cell Biotech Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
